Sustainable Access to Medicines in Europe
Brussels, Strasbourg and London – Europe is of great importance for Germany’s largest trade association of the industry, the ʻGerman Medicines Manufacturers’ Association’ (BAH). Through our European umbrella organization, the ‘Association of the European Self-Medication Industry’ (AESGP), we are right in the heart of the European quarter in Brussels, and maintain close contacts to European institutions and the numerous different organizations on site. As part of our enhanced commitment to European politics, BAH has compiled this new publication entitled ‘Sustainable Access to Medicines in Europe – Priorities for a Modern EU Health Policy’.
The European system for marketing authorisation of medicinal products, harmonised provisions for pharmacovigilance, the single European market, as well as free movement of persons in Europe, are important factors from which the pharmaceutical industry has already gained benefits for many years. They have also significantly improved the access of patients to medicines in Europe. Europe will continue to assume its role of a pioneer in innovation as well as quality and safety of medicines.
The present publication describes the broad spectrum of topics in which BAH engages at the European level: from the Brexit to the new EU ‘Medical Device Regulation’ (MDR) and the European ‘Health Technology Assessment’ cooperation (HTA), from the EU Falsified Medicines Directive to health claims and the EU Regulation on clinical studies.
The engagement of BAH at European level is multifaceted. In times of crisis in Europe, the pharmaceutical industry feels even more committed to the European idea – and this publication should be understood in this sense.